Now, it’s worth noting Stock Advisor’s total average return is 1,062% — a market-crushing outperformance compared to 194 % ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...

Omalizumab had the greatest risk for adverse effects and dupilumab had the most favorable safety profile among biologics for patients with asthma, according to an abstract presented at the CHEST ...

This is an active lawsuit, and none of the allegations against the defendant(s) have been proven. The contents of this page reflect the allegations in the lawsuits. Cutaneous T-cell lymphoma (CTCL) is ...

Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic ...

Despite the rejection, analysts saw Regeneron’s use of an alternate filler for Eylea HD as a positive development, with BMO Capital Markets noting that this could signal the end of manufacturing ...

The drug dupilumab (Dupixent) effectively clears up airways plugged by mucus during an asthma attack, researchers reported Oct. 27 in the American Journal of Respiratory and Critical Care Medicine.

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its eczema treatment, Dupixent, and cancer treatment Libtayo, sending shares up ...